Terms: = Kidney tumors AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Clinical Outcome
88 results:
1. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract] [Full Text] [Related]
2. Co-Expression of Multiple
Li L; Li CG; Almomani SN; Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511191
[TBL] [Abstract] [Full Text] [Related]
3. Vascular endothelial profilin-1 drives a protumorigenic tumor microenvironment and tumor progression in renal cancer.
Gau D; Daoud A; Allen A; Joy M; Sagan A; Lee S; Lucas PC; Duensing S; Boone D; Osmanbeyoglu HU; Roy P
J Biol Chem; 2023 Aug; 299(8):105044. PubMed ID: 37451478
[TBL] [Abstract] [Full Text] [Related]
4. Remarkable 107-year-old kidney with a 49-year of long-term allograph survival through continuous azathioprine monotherapy.
Nascimento E; Filho AS; Lucas-Junior FDM; Jobim LFJ; Lasmar MF; Tavares-Filho HA; Fabreti-Oliveira RA
Transpl Immunol; 2023 Jun; 78():101821. PubMed ID: 36921732
[TBL] [Abstract] [Full Text] [Related]
5. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor clinical outcome.
Lucarelli G; Rutigliano M; Loizzo D; di Meo NA; Lasorsa F; Mastropasqua M; Maiorano E; Bizzoca C; Vincenti L; Battaglia M; Ditonno P
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430448
[TBL] [Abstract] [Full Text] [Related]
6. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
Konaté MM; Li MC; McShane LM; Zhao Y
Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis.
Wu Z; Lin Y; Liu LM; Hou YL; Qin WT; Zhang L; Jiang SH; Yang Q; Bai YR
J Immunol Res; 2022; 2022():7978042. PubMed ID: 35983076
[TBL] [Abstract] [Full Text] [Related]
8. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract] [Full Text] [Related]
9. Relevance of CYP3A5 Expression on the clinical outcome of Patients With Renal Cell Carcinoma.
Matsumoto J; Kotera Y; Watari S; Takeuchi K; Ueki H; Koyama T; Wada K; Fujiyoshi M; Nasu Y; Ariyoshi N
Anticancer Res; 2021 May; 41(5):2511-2521. PubMed ID: 33952479
[TBL] [Abstract] [Full Text] [Related]
10. SNHG12 promotes carcinogenesis of human renal cell cancer via functioning as a competing endogenous RNA and sponging miR-30a-3p.
Yu H; Liu J; Zhang Z; Zhu Y; Bi J; Kong C
J Cell Mol Med; 2021 May; 25(10):4696-4708. PubMed ID: 33787057
[TBL] [Abstract] [Full Text] [Related]
11. Inverse correlation of miR-27a-3p and CDH5 expression serves as a diagnostic biomarker of proliferation and metastasis of clear cell renal carcinoma.
Wang Y; Zhou X; Han P; Lu Y; Zhong X; Yang Y; Li D; Liu D; Li Q; Pan N; Mo Y; Luo W; Li P; Zhou X; Liudmila M
Pathol Res Pract; 2021 Apr; 220():153393. PubMed ID: 33740544
[TBL] [Abstract] [Full Text] [Related]
12. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract] [Full Text] [Related]
13. Predicative value of IFITM2 in renal clear cell carcinoma: IFITM2 is associated with lymphatic metastasis and poor clinical outcome.
Yang N; Liu Z; Pang S; Wu J; Liang J; Sun L
Biochem Biophys Res Commun; 2021 Jan; 534():157-164. PubMed ID: 33308825
[TBL] [Abstract] [Full Text] [Related]
14. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract] [Full Text] [Related]
15. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
16. Blastemal NCAM
Raved D; Tokatly-Latzer I; Anafi L; Harari-Steinberg O; Barshack I; Dekel B; Pode-Shakked N
Pathol Res Pract; 2019 Aug; 215(8):152491. PubMed ID: 31202518
[TBL] [Abstract] [Full Text] [Related]
17. Renal Epithelioid Angiomyolipoma Undergoing Aggressive clinical outcome: The MDM2 Expression in Tumor Cells of Two Cases.
Inoue C; Saito R; Nakanishi W; Kumata H; Eba S; Fujishima F; Watanabe M; Sasano H
Tohoku J Exp Med; 2019 Feb; 247(2):119-127. PubMed ID: 30799331
[TBL] [Abstract] [Full Text] [Related]
18. Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma.
Andrejeva D; Kugler JM; Nguyen HT; Malmendal A; Holm ML; Toft BG; Loya AC; Cohen SM
BMC Cancer; 2018 Nov; 18(1):1180. PubMed ID: 30486822
[TBL] [Abstract] [Full Text] [Related]
19. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract] [Full Text] [Related]
20. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract] [Full Text] [Related]
[Next]
